Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (542)	6/5/2003 2:13:38 AM
From: Miljenko Zuanic	Respond to of 897

Twice may not be enough. You need at least three time (to eliminate noise) to learn lesson. <grrr> Anyway, reason for EMIS pop today: Abstract Number: 12-LB Authors: MIRIAM KIDRON, MICHAEL GOLDBERG, STEVE DINH, EHUD ARBIT, HANOCH BAR-ON Institution: Jerusalem, Israel; Tarrytown, NY Results: In type -2 diabetic (T2DM) patients, unrestrained hepatic glucose production (HGP) caused by hepatic insulin deficiency or resistance is considered the cause of the raised morning fasting blood glucose (FBG). It was hypothesized that bedtime administration of insulin directly to the liver by the portal route, might decrease FBG and lower endogenous insulin requirement and hence secretion.[br]Direct portal insulin delivery is made possible by the oral form of insulin developed by Emisphere Technology, which relies on its eligen carrier technology. A specific carrier, when combined with insulin, has been shown to enhance the gastrointestinal absorption of human insulin following oral administration in rats and primates. The mechanism by which the carrier facilitates gastrointestinal absorption of insulin, has not been fully elucidated. The current working hypothesis is that the carrier interacts non-covalently with insulin, thus, creating more favorable physico-chemical properties for absorption.[br]Twenty T2DM subjects (mean age 57 years [age range: 46-70], mean HbA1c 7.5%[br][Range 5.9-11.6%] mean BMI 28.7 kg/m[sup2] [range 21-3]) participated in the study. FBG, C-peptide and insulin levels were measured on two occasions, before the bedtime oral insulin dosing (baseline) and again on the night of, and the morning following, the oral dosing. The oral dose consisted of a dry powder mixture containing 300mg carrier and 300U or 400U insulin.[br]Bedtime oral insulin administration resulted in a 33% reduction in plasma insulin levels from 13.90[plusmn] 6.44[micro]U/ml to 9.35 [plusmn]4.52 (P[lt]0.001), and 24% reduction in plasma C-peptide, from 2.69[plusmn]0.88ng/ml to 2.04[plusmn]0.71 (p[lt]0.001). A 6% decrease in glucose from 133.78[plusmn] 40.53 mg/dl to 125.78[plusmn]42.99 (P=0.17) occurred the morning after ingestion of the oral insulin capsule.[br]This study suggests that a single dose of oral insulin given to patients with T2DM at bedtime, suppresses the overnight endogenous insulin secretion, thus reducing the demand on the islet cells. The long-term implications of the effects of oral bedtime insulin supplement in T2DM patients are potentially important and deserving of further studies. Category: Clinical Therapeutics/New Technology